FDA Clearance Tracker · K203136
Diazyme PLAC® Test for Lp-PLA2 Activity
Last checked: Nov 20, 2026Latest source record: Aug 6, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Aug 6, 2021
Substantially Equivalent
Time to decision
290 days
Received Oct 20, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K203136
- Device name
- Diazyme PLAC® Test for Lp-PLA2 Activity
- Applicant
- Diazyme Laboratories, Inc.
- Applicant location
- Poway, CA
- Received
- Oct 20, 2020
- Decided
- Aug 6, 2021
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.5600
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NOE. The earliest in FDA's data is K030477, decided Jul 18, 2003.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K203136
- The applicant filed a statement instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Diazyme Laboratories, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K253069 · Decided Jun 16, 2026 · 266 days after receipt
Device type: Lipoprotein, Low-Density, Antigen, Antiserum, Control (DFC) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.